WS
IRD

Wedbush Securities’s Opus Genetics IRD Stock Holding History

Wedbush Securities’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,825
Closed -$48K – 991
2020
Q3 		$48K Buy
5,825
+1,825
+46% +$17.8K ﹤0.01% 886
2020
Q2 		$45K Buy
+4,000
New +$36.8K ﹤0.01% 913
2019
Q2 		– Sell
-531
Closed -$13K – 1036
2019
Q1 		$13K Hold
531
– – ﹤0.01% 918
2018
Q4 		$24K Hold
531
– – ﹤0.01% 814
2018
Q3 		$45K Hold
531
– – 0.01% 875
2018
Q2 		$36K Hold
531
– – ﹤0.01% 850
2018
Q1 		$39K Hold
531
– – 0.01% 793
2017
Q4 		$52K Hold
531
– – 0.01% 820
2017
Q3 		$62K Buy
531
+312
+142% +$33.6K 0.01% 800
2017
Q2 		$30K Buy
+219
New +$42.6K ﹤0.01% 818

Other funds holding IRD

ACM
Altium Capital Management New York $42M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Wedbush Securities's IRD Position: Q4 2020 in Review

Wedbush Securities sold out of Opus Genetics (IRD) in Q4 2020, closing a stake of 5,825 shares — an estimated $48K sold.

Wedbush Securities first reported a position in IRD in Q2 2017 and held it in 10 quarters. The position peaked at $62K in Q3 2017. 14 funds tracked by Wall St. Rank hold IRD as of Q4 2020.

  • Wedbush Securities reported no remaining Opus Genetics position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 5,825 Opus Genetics shares in Q4 2020, an estimated $48K.
  • Wedbush Securities first reported a position in Opus Genetics in Q2 2017 and held it in 10 quarters.
  • Wedbush Securities's Opus Genetics position peaked at $62K in Q3 2017.
  • 14 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.